Orkambi Treatment in 2 to 5 Year Old Children With CF
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Vertex Pharmaceuticals Incorporated
Related studies linked through entity extraction aliases.
Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects
- Status
- COMPLETED
- Phase
- N/A
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
- Status
- COMPLETED
- Phase
- PHASE2
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
- Status
- COMPLETED
- Phase
- PHASE3
A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
- Status
- TERMINATED
- Phase
- PHASE3
A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
- Status
- COMPLETED
- Phase
- PHASE3
A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
- Status
- COMPLETED
- Phase
- PHASE1
A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
- Status
- TERMINATED
- Phase
- PHASE3
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
- Status
- COMPLETED
- Phase
- PHASE3
Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF
- Status
- COMPLETED
- Phase
- N/A